BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32905127)

  • 1. Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction.
    Kanukurti J; Mohammed N; Sreedevi NN; Khan SA; Baba KSSS; Bhaskar MV; Satish OS; Naushad SM; Mohan IK
    J Lab Physicians; 2020 Aug; 12(2):126-132. PubMed ID: 32905127
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction.
    Polat V; Bozcali E; Uygun T; Opan S; Karakaya O
    Acta Cardiol; 2016 Apr; 71(2):191-7. PubMed ID: 27090041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction.
    Gergei I; Krämer BK; Scharnagl H; Stojakovic T; März W
    Peptides; 2019 Jan; 111():112-117. PubMed ID: 29684593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum NT-proBNP and TUG1 as novel biomarkers for elderly hypertensive patients with heart failure with preserved ejection fraction.
    Zhang S; Jin R; Li B
    Exp Ther Med; 2021 May; 21(5):446. PubMed ID: 33747182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
    Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
    Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
    Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
    Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle.
    Kirillova VV; Sokolova LA; Meshchaninov VN; Pershanova VI
    Ter Arkh; 2018 Sep; 90(9):68-72. PubMed ID: 30701738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction.
    Tanacli R; Hashemi D; Neye M; Motzkus LA; Blum M; Tahirovic E; Dordevic A; Kraft R; Zamani SM; Pieske B; Düngen HD; Kelle S
    ESC Heart Fail; 2020 Oct; 7(5):3240-3245. PubMed ID: 32567247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in clinical biochemical indexes of patients with heart failure with preserved ejection fraction or patients with hypertensive heart disease before and after treadmill exercise.
    Yang X; Xing Y; Li K
    Ann Palliat Med; 2021 Jul; 10(7):7970-7976. PubMed ID: 34353083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of microalbuminuria in the diagnosis of heart failure with preserved ejection fraction.
    Chen L; Jin C; Chen L; Li M; Zhong Y; Xu Y
    Herz; 2021 Sep; 46(Suppl 2):215-221. PubMed ID: 33118081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.